Induction regimen: results and toxicity
. | Without quinine, n = 212 . | With quinine, n = 213 . | P . |
|---|---|---|---|
| Number of patients in CR (%) | 171 (80.6) | 173 (81.2) | NS |
| CR after 1 course of induction, n (%) | 139 (65.6) | 145 (68.1) | NS |
| CR after 2 courses of induction, n (%) | 32 (15.1) | 28 (13.1) | NS |
| Time to discharge from hospital, d (range) | 31 (19-100) | 30 (16-81) | NS |
| Duration of neutropenia of fewer than 0.5 G/L, d (range) | 26 (11-102) | 25 (9-67) | NS |
| Duration of thrombopenia of fewer than 100 G/L, d (range) | 22 (8-134) | 23 (9-96) | NS |
| Red cell transfusion, units (range) | 11 (3-50) | 12 (2-38) | NS |
| Platelet transfusion, units (range) | 8 (0-40) | 9 (1-40) | NS |
| Duration of intravenous antibiotics, d (range) | 25 (0-100) | 25 (0-66) | NS |
| Duration of intravenous antifungal agents, d (range) | 9 (0-60) | 12 (0-60) | NS |
| Early death, n (%) | 3 (1.4) | 1 (0.5) | NS |
| Death in aplasia, n (%) | 6 (2.8) | 12 (5.7) | NS |
| Failure, n (%) | 32 (15.1) | 27 (12.7) | NS |
| Toxicity—NCI grade above 2, % | |||
| Mucositis | 10.2 | 17.2 | .05 |
| Nausea/vomiting | 3.9 | 4.4 | NS |
| GI tract | 6.3 | 8.1 | NS |
| Kidney | 1.5 | 2.5 | NS |
| Liver | 16.4 | 23.1 | NS |
| Central nervous system | 3.4 | 4.4 | NS |
. | Without quinine, n = 212 . | With quinine, n = 213 . | P . |
|---|---|---|---|
| Number of patients in CR (%) | 171 (80.6) | 173 (81.2) | NS |
| CR after 1 course of induction, n (%) | 139 (65.6) | 145 (68.1) | NS |
| CR after 2 courses of induction, n (%) | 32 (15.1) | 28 (13.1) | NS |
| Time to discharge from hospital, d (range) | 31 (19-100) | 30 (16-81) | NS |
| Duration of neutropenia of fewer than 0.5 G/L, d (range) | 26 (11-102) | 25 (9-67) | NS |
| Duration of thrombopenia of fewer than 100 G/L, d (range) | 22 (8-134) | 23 (9-96) | NS |
| Red cell transfusion, units (range) | 11 (3-50) | 12 (2-38) | NS |
| Platelet transfusion, units (range) | 8 (0-40) | 9 (1-40) | NS |
| Duration of intravenous antibiotics, d (range) | 25 (0-100) | 25 (0-66) | NS |
| Duration of intravenous antifungal agents, d (range) | 9 (0-60) | 12 (0-60) | NS |
| Early death, n (%) | 3 (1.4) | 1 (0.5) | NS |
| Death in aplasia, n (%) | 6 (2.8) | 12 (5.7) | NS |
| Failure, n (%) | 32 (15.1) | 27 (12.7) | NS |
| Toxicity—NCI grade above 2, % | |||
| Mucositis | 10.2 | 17.2 | .05 |
| Nausea/vomiting | 3.9 | 4.4 | NS |
| GI tract | 6.3 | 8.1 | NS |
| Kidney | 1.5 | 2.5 | NS |
| Liver | 16.4 | 23.1 | NS |
| Central nervous system | 3.4 | 4.4 | NS |
CR indicates complete remission; GI, gastrointestinal; and NS, not significant.